Charles River Laboratories International, Inc. (NYSE:CRL) Given Average Recommendation of “Reduce” by Analysts

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have been assigned a consensus rating of “Reduce” from the sixteen brokerages that are covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $209.00.

A number of research firms have commented on CRL. Evercore ISI upped their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. Redburn Atlantic assumed coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They set a “sell” rating and a $151.00 price objective for the company. Bank of America cut their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Citigroup lowered Charles River Laboratories International from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $215.00 to $175.00 in a research report on Tuesday, October 1st. Finally, TD Cowen lifted their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $163.77 on Monday. The business’s 50 day moving average price is $190.64 and its 200 day moving average price is $198.40. The company has a market cap of $8.37 billion, a price-to-earnings ratio of 20.50, a PEG ratio of 6.62 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. Charles River Laboratories International has a one year low of $160.85 and a one year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.43 by $0.16. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.72 EPS. On average, research analysts predict that Charles River Laboratories International will post 10.18 EPS for the current year.

Insider Activity

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Charles River Laboratories International

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new position in shares of Charles River Laboratories International in the 3rd quarter valued at approximately $601,000. JPMorgan Chase & Co. lifted its holdings in shares of Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after purchasing an additional 85,759 shares during the period. State Street Corp grew its position in Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after buying an additional 41,421 shares during the last quarter. Janus Henderson Group PLC increased its stake in Charles River Laboratories International by 7.6% in the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock valued at $9,064,000 after buying an additional 3,268 shares during the period. Finally, Neo Ivy Capital Management purchased a new position in Charles River Laboratories International during the 3rd quarter worth $966,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).